# Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/ranibizumab-versus-bevacizumab-to-treat-neovascular-age-related-macular/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Usha Chakravarthy,Simon Harding,Chris Rogers,Susan M. Downes,Andrew Lotery,Sarah Wordsworth,Barnaby C Reeves |
| Citations | 779 |
| DOI | 10.1016/j.ophtha.2012.04.015 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2146673937 |
| PMID | 22578446 |
| Type | article |
| Year | 2012 |

## Paper authors

- [Chris Rogers](https://scholariq.org/researchers/chris-rogers/)

## Paper journal

- [Ophthalmology](https://scholariq.org/journals/ophthalmology/)

## Paper primary topic

- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)

## Paper topics

- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)
- [Ophthalmology and Visual Impairment Studies](https://scholariq.org/topics/ophthalmology-and-visual-impairment-studies/)
- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.